Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
December 23, 2013BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office of the Chief Scientist
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Dec. 23, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2014 of 6.1 million Shekels (approximately $1.74 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product in development by Cell Cure for the treatment of ... 
Printer Friendly Version
December 06, 2013LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.11
New Release Features showcasing of gene-relevant scientific conferences ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 6, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards®, Version 3.11. The new release is available at www.genecards.org. GeneCards® is a comprehensive online database that provides comprehensive information on all human genes. It is accessed by professionals in... 
Printer Friendly Version
December 02, 2013Asterias Biotherapeutics, Inc. Files Registration Statement for Underwritten Public Offering
MENLO PARK and ALAMEDA, Calif., December 2, 2013 –Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that Asterias has filed a registration statement with the Securities and Exchange Commission for an underwritten public offering of up to $15,000,000 of units with each unit consisting of one share of Series B common stock and one redemption right.  The shares of Series B common stock and redemption rights will immediately be freely tradable as sep... 
Printer Friendly Version
October 28, 2013Asterias Biotherapeutics, Inc. Plans to File Registration Statement for Underwritten Public Offering
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013-- Asterias Biotherapeutics, Inc., a majority-owned subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it plans to file a registration statement with the Securities and Exchange Commission in November 2013 for an underwritten public offering of units, with each unit consisting of one share of Series B common stock, $0.0001 par value per share, and one redemption right ... 
Printer Friendly Version
October 15, 2013BioTime’s Subsidiary OncoCyte Corporation and The Wistar Institute To Collaboratively Develop Cancer Diagnostics
- PanC-DxTM Markers to be Tested in Multi-Center Lung Cancer Study Currently Underway - ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 15, 2013-- BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Institute to collaboratively develop lung cancer diagnostic products. As part of the collaboration, Wistar inv... 
Printer Friendly Version
October 01, 2013Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 1, 2013-- Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset Contribution Agreement (the “Agreement”) with Geron Corporation, previously announced on January 7, 2013, pursuant to which Asterias Biotherapeutics acquired Geron’s human embryonic stem (hES) cell assets, as well as rights to use certain human em... 
Printer Friendly Version
August 06, 2013LifeMap Sciences, a Subsidiary of BioTime, Announces Release of MalaCards Version 1.04
ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of MalaCards, Version 1.04. The new release is available at http://www.malacards.org. MalaCards is a new database of human diseases and their annotations that is modeled on the architecture and richness of the popular GeneCards® database of human genes (http://www.genecards.org). LifeMap Sciences holds the exclusive worldwide license to marketMalaCards&nbs... 
Printer Friendly Version
August 05, 2013BioTime’s Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker
- FSIP1 is one component of a panel of markers comprising PanC-DxTM, a blood-based cancer screen - ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 5, 2013-- BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation today announced the publication of a scientific report on the gene FSIP1 and its potential as a marker for breast cancer. The paper, published in the peer-reviewed journal Biomarkers in Medicine and available online ... 
Printer Friendly Version
July 26, 2013LifeMap Sciences Announces Release of LifeMap DiscoveryTM Version 1.2 with Extensive Stem Cell Therapy Data
ALAMEDA, Calif., July 26, 2013 – LifeMap Sciences, Inc. announced today the release of LifeMap Discovery™ version 1.2 (discovery.lifemapsc.com) . LifeMap Discovery™ is a state-of-the-art roadmap of embryonic development and stem cell biology. The product integrates embryonic development and stem cell biology, molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and bioinformatics applications. As such, it is a unique and powerful tool for resear... 
Printer Friendly Version
July 18, 2013BioTime Subsidiary LifeMap Sciences Announces Publication of Research Report Describing LifeMap Discovery™
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 18, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that the LifeMap Discovery™ product has been documented in a published paper authored by LifeMap Sciences’ research and development team. LifeMap Discovery™ (available as of November 2012 via http://discovery.lifemapsc.com/) is the first “roadmap” directing scientists through the many hundreds of branch points in... 
Printer Friendly Version
May 13, 2013BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--May. 13, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences) today announced that Cell Cure Neurosciences has been awarded a grant of 5.34 million Shekels, approximately $1.5 million, for 2013 from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product in development by Cell Cure ... 
Printer Friendly Version
April 30, 2013LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.10
New Release Features “Super-Pathways” and Collaboration with Lost Island Labs, Inc. ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 30, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards®, Version 3.10. The new release is available at www.genecards.org. LifeMap Sciences holds the exclusive worldwide license to market GeneCards® from Yeda Research and Development Company Ltd., the comme... 
Printer Friendly Version
April 23, 2013LifeMap Sciences, a Subsidiary of BioTime, Announces Partnership with Appistry
Agreement will integrate critical sources of genetic and disease information into Appistry’s next-generation sequencing (“NGS”) reports for clinicians ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 23, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX), announced today a collaborative partnership and value-added reseller agreement with Appistry, Inc., which provides big-data computing that supports life-science and medical ana... 
Printer Friendly Version
April 18, 2013LifeMap Sciences Announces Publication of Research Report Describing the MalaCards Database of Human Diseases
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 18, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that its MalaCards database has been recognized in a published paper by the Weizmann Institute of Science research group under the supervision of Prof. Doron Lancet from the Department of Molecular Genetics, in collaboration with LifeMap Sciences. MalaCards (available as of Oct 2012 via www.malacards.org), is a d... 
Printer Friendly Version
April 10, 2013LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene
- BioTime Subsidiary offers 100 select recombinant proteins in its BioReagents Portal - ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 10, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it is now offering 100 selected ProSpec-Tany TechnoGene (ProSpec) manufactured recombinant proteins related to stem cell research in its recently launched LifeMap BioReagents™ portal (http://bioreagents.lifemapsc.com)... 
Printer Friendly Version
March 25, 2013LifeMap Sciences, a Subsidiary of BioTime, Announces Release of LifeMap Discovery™ Version 1.1 with Enhanced Therapeutic Discovery and Commercial Utility
ALAMEDA, Calif., March 25, 2013 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of LifeMap Discovery™ version 1.1 (discovery.lifemapsc.com). LifeMap Discovery™ is a key component in LifeMap’s integrated database suite, a discovery platform for biomedical and stem cell research, which also includes GeneCards®, the leading human gene database, and MalaCards, the human disease database. LifeMap Discovery™ version 1.1 includes significant enhancem... 
Printer Friendly Version
February 11, 2013LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique Visitors Annually according to Google Analytics
- Company describes new product plans aimed at further monetizing these assets - ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 11, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX), announced today that according to Google Analytics, the Company’s databases have attracted over two million unique visitors in the previous 12 months. Since the announcement of the acquisition of Xennex in May 2012, LifeMap launched LifeM... 
Printer Friendly Version
January 31, 2013BioTime’s Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM
Multi-center clinical study of a blood-based diagnostic test for the early detection of cancer planned for 2013 ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 31, 2013-- BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation provided an update on the progress of development of PanC-DxTM, a novel blood-based diagnostic test utilizing molecular markers discovered at BioTime and OncoCyte designed to detect the presence of var... 
Printer Friendly Version
January 30, 2013LifeMap Sciences, a Subsidiary of BioTime, Announces Publication of Research Report Describing Non-Redundant Compendium of Human Non-Coding RNA Authored by GeneCards® Scientists
Report shows the existence of ∼80,000 human non-redundant non-coding RNAs covering 71% of the human genome, slightly less than the ENCODE prediction of 80% ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 30, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the publication of a paper authored by a research group under the supervision of Prof. Doron Lancet from the Department of Molecular Genetics at t... 
Printer Friendly Version
January 09, 2013LifeMap Sciences, a Subsidiary of BioTime, Inc., Announces the Release of MalaCards Version 1.02
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 9, 2013-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of MalaCards version 1.02 on January 7. The new release is available at www.malacards.org. MalaCards is a new database of human diseases and their annotations that is modeled on the architecture and richness of the popular GeneCards® database of human genes. LifeMap Sciences holds the exclusive wor... 
Printer Friendly Version